pemphigus vulgaris is a life threatening relapsing disease, the first line in its
treatment is systemic steroids, and due to the high rate of side effects caused by systemic steroids in
pemphigus vulgaris patients, some immunosuppressant drugs have
been introduced as an adjuvant
steroid sparing agents, and one of these immunosuppressants is methotrexate, and in spite of the lack of
its use in pemphigus vulgaris, a few studies have shown an encouraging results of its use, and have advised
to carry out more studies about it as an immunosuppressant which has been omitted from usage in
pemphigus vulgaris for a long time.
